GillesSallesMD

Hematologic Oncology

Physician

Overview of Dr. Salles

Dr. Gilles Salles is an oncologist based in New York, NY, with a subspecialty in hematologic oncology, particularly experienced in lymphoma. He graduated from Université Claude Bernard Lyon in 1989. His recent publications focus on lymphoma-related topics, including CAR T-cell therapy and treatment strategies for diffuse large B-cell and follicular lymphoma, published in top tier journals such as New England Journal of Medicine, JCO, Blood and others. Dr. Salles is actively involved in multiple trials concerning treatments for various types of lymphoma, serving as a contact and principal investigator for studies exploring novel therapeutic combinations.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(231) 680-2531

Education & Training

Université Claude Bernard LyonClass of 1989

Certifications & Licensure

NY State Medical License 2021 - 2027

Awards, Honors, & Recognition

T Howard Lee Keynote Lecture 20th Annual Indy Hematology Review, 2023
Steven Greenberg Chair MKS, 2021
Clinicak Keynote Speaker 18th International Ultmann Chicago Lymphoma Symposium, 2021
Jose Carreras EHA Award European Haematology Association, 2020
Join now to see all

Clinical Trials

A Study of Mosunetuzumab in People With Follicular Lymphoma Start of enrollment: 2022 May 27
RECRUITING
PHASE2
Roles: Contact
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. Start of enrollment: 2020 Jun 11
RECRUITING
PHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Start of enrollment: 2023 Sep 18
RECRUITING
PHASE3
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2022 Aug 18
RECRUITING
PHASE1
A Study of Glofitamab and Lenalidomide in People with Mantle Cell Lymphoma Start of enrollment: 2024 Jan 08
RECRUITING
PHASE1
Roles: Contact
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas Start of enrollment: 2023 Dec 29
RECRUITING
PHASE1, PHASE2
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Start of enrollment: 2023 Mar 14
TERMINATED
PHASE2
Roles: Contact
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma Start of enrollment: 2021 May 04
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Roles: Contact
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Start of enrollment: 2019 May 29
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.
Marek Trněný, Laura Maria Fogliato, Faithlore Gardner, Ian W Flinn, Jean-François Larouche
Blood Advances. 2025-03-15
1 citations
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2025-03-10
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.
Danny Luan, Susan DeWolf, Teng Fei, Sandeep Raj, Gunjan L Shah
Blood Cancer Discovery. 2025-03-04

Press Mentions

DLBCL: Polatuzumab Vedotin Enhances Progression-Free SurvivalDecember 17th, 2021
DLBCL: PFS but No OS Benefit with Polatuzumab-Vedotin Add-OnDecember 17th, 2021
$Incyte : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL$
Incyte : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCLJune 9th, 2021
Join now to see all